Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

A Bayesian Filtering Approach for Tracking Arousal from Binary and Continuous Skin Conductance Features.

Wickramasuriya DS, Faghih RT.

IEEE Trans Biomed Eng. 2019 Oct 4. doi: 10.1109/TBME.2019.2945579. [Epub ahead of print]

PMID:
31603767
2.

Skin Conductance as a Viable Alternative for Closing the Deep Brain Stimulation Loop in Neuropsychiatric Disorders.

Wickramasuriya DS, Amin MR, Faghih RT.

Front Neurosci. 2019 Aug 7;13:780. doi: 10.3389/fnins.2019.00780. eCollection 2019.

3.

Design of Intermittent Control for Cortisol Secretion under Time-Varying Demand and Holding Cost Constraints.

Taghvafard H, Cao M, Kawano Y, Faghih RT.

IEEE Trans Biomed Eng. 2019 May 22. doi: 10.1109/TBME.2019.2918432. [Epub ahead of print]

PMID:
31135341
4.

Sparse Deconvolution of Electrodermal Activity via Continuous-Time System Identification.

Amin MR, Faghih RT.

IEEE Trans Biomed Eng. 2019 Sep;66(9):2585-2595. doi: 10.1109/TBME.2019.2892352. Epub 2019 Jan 10.

PMID:
30629490
5.

A State-Space Approach for Detecting Stress from Electrodermal Activity.

Wickramasuriya DS, Qi C, Faghih RT.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:3562-3567. doi: 10.1109/EMBC.2018.8512928.

PMID:
30441148
6.

Altered ultradian cortisol rhythmicity as a potential neurobiologic substrate for chronic insomnia.

Vargas I, Vgontzas AN, Abelson JL, Faghih RT, Morales KH, Perlis ML.

Sleep Med Rev. 2018 Oct;41:234-243. doi: 10.1016/j.smrv.2018.03.003. Epub 2018 Mar 27. Review.

7.

Automated ovarian follicular monitoring: A novel real-time approach.

Faghih RT, Styer AK, Brown EN.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:632-635. doi: 10.1109/EMBC.2017.8036904.

PMID:
29059952
8.

Characterization of fear conditioning and fear extinction by analysis of electrodermal activity.

Faghih RT, Stokes PA, Marin MF, Zsido RG, Zorowitz S, Rosenbaum BL, Huijin Song, Milad MR, Dougherty DD, Eskandar EN, Widge AS, Brown EN, Barbieri R.

Conf Proc IEEE Eng Med Biol Soc. 2015 Aug;2015:7814-8. doi: 10.1109/EMBC.2015.7320204.

PMID:
26738104
9.

Estimating a dynamic state to relate neural spiking activity to behavioral signals during cognitive tasks.

Xinyi Deng, Faghih RT, Barbieri R, Paulk AC, Asaad WF, Brown EN, Dougherty DD, Widge AS, Eskandar EN, Eden UT.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7808-13. doi: 10.1109/EMBC.2015.7320203.

10.

An optimization formulation for characterization of pulsatile cortisol secretion.

Faghih RT, Dahleh MA, Brown EN.

Front Neurosci. 2015 Aug 11;9:228. doi: 10.3389/fnins.2015.00228. eCollection 2015.

11.

Quantifying Pituitary-Adrenal Dynamics and Deconvolution of Concurrent Cortisol and Adrenocorticotropic Hormone Data by Compressed Sensing.

Faghih RT, Dahleh MA, Adler GK, Klerman EB, Brown EN.

IEEE Trans Biomed Eng. 2015 Oct;62(10):2379-88. doi: 10.1109/TBME.2015.2427745. Epub 2015 Apr 29.

12.

Deconvolution of serum cortisol levels by using compressed sensing.

Faghih RT, Dahleh MA, Adler GK, Klerman EB, Brown EN.

PLoS One. 2014 Jan 28;9(1):e85204. doi: 10.1371/journal.pone.0085204. eCollection 2014.

13.

A feedback control model for cortisol secretion.

Faghih RT, Savla K, Dahleh MA, Brown EN.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:716-9. doi: 10.1109/IEMBS.2011.6090162.

PMID:
22254410
14.

Broad range of neural dynamics from a time-varying FitzHugh-Nagumo model and its spiking threshold estimation.

Faghih RT, Savla K, Dahleh MA, Brown EN.

IEEE Trans Biomed Eng. 2012 Mar;59(3):816-23. doi: 10.1109/TBME.2011.2180020. Epub 2011 Dec 16.

PMID:
22186931
15.

The Fitzhugh-Nagumo model: Firing modes with time-varying parameters & parameter estimation.

Faghih RT, Savla K, Dahleh MA, Brown EN.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:4116-9. doi: 10.1109/IEMBS.2010.5627326.

PMID:
21096631
16.

Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.

Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, Ween H, Curtis MP, Sarris KA, Gfesser GA, El-Kouhen R, Robb HM, Radek RJ, Marsh KC, Bunnelle WH, Gopalakrishnan M.

J Med Chem. 2009 May 28;52(10):3377-84. doi: 10.1021/jm9003818.

PMID:
19419141
17.

In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile.

Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, Wetterstrand C, Briggs CA, Faghih R, Bunnelle WH, Gopalakrishnan M.

J Pharmacol Exp Ther. 2009 Jul;330(1):257-67. doi: 10.1124/jpet.109.151886. Epub 2009 Apr 23.

PMID:
19389923
18.

External periodic driving of large systems of globally coupled phase oscillators.

Antonsen TM Jr, Faghih RT, Girvan M, Ott E, Platig J.

Chaos. 2008 Sep;18(3):037112. doi: 10.1063/1.2952447.

PMID:
19045486
19.

Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.

Faghih R, Gfesser GA, Gopalakrishnan M.

Recent Pat CNS Drug Discov. 2007 Jun;2(2):99-106. Review.

PMID:
18221220
20.

Allosteric modulators of the alpha7 nicotinic acetylcholine receptor.

Faghih R, Gopalakrishnan M, Briggs CA.

J Med Chem. 2008 Feb 28;51(4):701-12. doi: 10.1021/jm070256g. Epub 2008 Jan 17. Review. No abstract available.

PMID:
18198823
21.

Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.

Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA.

Biochem Pharmacol. 2007 Apr 15;73(8):1243-55. Epub 2007 Feb 23.

PMID:
17371699
22.

Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Witte DG, Yao BB, Miller TR, Carr TL, Cassar S, Sharma R, Faghih R, Surber BW, Esbenshade TA, Hancock AA, Krueger KM.

Br J Pharmacol. 2006 Jul;148(5):657-70. Epub 2006 May 22.

23.

Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor.

Yao BB, Witte DG, Miller TR, Carr TL, Kang CH, Cassar S, Faghih R, Bennani YL, Surber BW, Hancock AA, Esbenshade TA.

Neuropharmacology. 2006 Mar;50(4):468-78. Epub 2005 Nov 28.

PMID:
16316670
24.

Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.

Sun M, Zhao C, Gfesser GA, Thiffault C, Miller TR, Marsh K, Wetter J, Curtis M, Faghih R, Esbenshade TA, Hancock AA, Cowart M.

J Med Chem. 2005 Oct 6;48(20):6482-90. Erratum in: J Med Chem. 2012 Jan 12;55(1):563.

PMID:
16190774
25.

Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.

Esbenshade TA, Yao BB, Witte DG, Carr TL, Sharma R, Baranowski JL, Krueger KM, Miller TR, Surber BW, Faghih R, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S46-7. No abstract available.

PMID:
15928830
26.

Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.

Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB.

Inflamm Res. 2005 Apr;54 Suppl 1:S27-9. No abstract available.

PMID:
15928821
27.

Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists.

Cowart M, Faghih R, Gfesser G, Curtis M, Sun M, Zhao C, Bennani Y, Wetter J, Marsh K, Miller TR, Krueger K, Pan JB, Drescher K, Fox GB, Esbenshade TA, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S25-6. No abstract available.

PMID:
15928820
28.

Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.

Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. No abstract available.

PMID:
15928819
29.

Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.

Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE.

Brain Res. 2005 May 31;1045(1-2):142-9. Epub 2005 Apr 20.

PMID:
15910772
30.

Structure-activity relationships of arylbenzofuran H3 receptor antagonists.

Gfesser GA, Faghih R, Bennani YL, Curtis MP, Esbenshade TA, Hancock AA, Cowart MD.

Bioorg Med Chem Lett. 2005 May 16;15(10):2559-63.

PMID:
15863316
31.

4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.

Cowart M, Faghih R, Curtis MP, Gfesser GA, Bennani YL, Black LA, Pan L, Marsh KC, Sullivan JP, Esbenshade TA, Fox GB, Hancock AA.

J Med Chem. 2005 Jan 13;48(1):38-55.

PMID:
15634000
32.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.

Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17.

PMID:
15608077
33.

Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists.

Cowart M, Altenbach R, Black L, Faghih R, Zhao C, Hancock AA.

Mini Rev Med Chem. 2004 Nov;4(9):979-92. Review.

PMID:
15544558
34.

In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.

Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB.

Basic Clin Pharmacol Toxicol. 2004 Sep;95(3):144-52.

35.

Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.

Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.

Biochem Pharmacol. 2004 Sep 1;68(5):933-45.

PMID:
15294456
36.

D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist.

Curtis MP, Dwight W, Pratt J, Cowart M, Esbenshade TA, Krueger KM, Fox GB, Pan JB, Pagano TG, Hancock AA, Faghih R, Bennani YL.

Arch Pharm (Weinheim). 2004 Apr;337(4):219-29.

PMID:
15146898
37.

Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties.

Faghih R, Esbenshade TA, Krueger KM, Yao BB, Witte DG, Miller TM, Kang CH, Fox GB, Cowart M, Bennani YL, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S79-80. Epub 2004 Mar 5. No abstract available.

PMID:
15054629
38.

Molecular and pharmacological characterization of the monkey histamine H(3) receptor.

Yao BB, Sharma R, Cassar S, Faghih R, Bennani Y, Esbenshade TA, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S75-6. Epub 2004 Mar 5. No abstract available.

PMID:
15054627
39.

The medicinal chemistry of novel H(3) antagonists.

Cowart M, Faghih R, Gfesser G, Curtis M, Pratt JK, Bennani Y, Fox GB, Esbenshade TA, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S69-70. Epub 2004 Mar 5. No abstract available.

PMID:
15054624
40.

Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animal models.

Fox GB, Pan JB, Lewis AM, Browman KE, Komater VA, Buckley MJ, Curzon P, Radek RJ, Faghih R, Esbenshade TA, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S49-50. Epub 2004 Mar 5. No abstract available.

PMID:
15054614
41.

Histamine H(3) antagonists in models of obesity.

Hancock AA, Bush EN, Jacobson PB, Faghih R, Esbenshade TA.

Inflamm Res. 2004 Mar;53 Suppl 1:S47-8. Epub 2004 Mar 5. No abstract available.

PMID:
15054613
42.

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.

Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB.

Eur J Pharmacol. 2004 Mar 8;487(1-3):183-97.

PMID:
15033391
43.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.

Gfesser GA, Zhang H, Dinges J, Fox GB, Pan JB, Esbenshade TA, Yao BB, Witte D, Miller TR, Kang CH, Krueger KM, Bennani YL, Hancock AA, Faghih R.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):673-6.

PMID:
14741266
44.

D-alanine piperazine-amides: novel non-imidazole antagonists of the histamine H3 receptor.

Faghih R, Phelan K, Esbenshade TA, Miller TR, Kang CH, Krueger KM, Yao BB, Fox GB, Bennani YL, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S47-8. No abstract available.

PMID:
12755406
45.

In vitro pharmacological properties of two novel non-imidazole H3 receptor (H3R) antagonists.

Yao BB, Witte DG, Miller TR, Krueger KM, Carr TL, Kang CH, Faghih R, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S45-6. No abstract available.

PMID:
12755405
46.

Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats.

Fox GB, Pan JB, Faghih R, Esbenshade TA, Lewis A, Bitner RS, Black LA, Bennani YL, Decker MW, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S31-2. No abstract available.

PMID:
12755398
47.

Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.

Faghih R, Dwight W, Pan JB, Fox GB, Krueger KM, Esbenshade TA, McVey JM, Marsh K, Bennani YL, Hancock AA.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1325-8.

PMID:
12657274
48.

Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.

Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):887-96. Epub 2003 Feb 20.

PMID:
12606603
49.

Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization.

Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):897-908. Epub 2003 Feb 20.

PMID:
12606600
50.

Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.

Faghih R, Dwight W, Vasudevan A, Dinges J, Conner SE, Esbenshade TA, Bennani YL, Hancock AA.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3077-9.

PMID:
12372505

Supplemental Content

Loading ...
Support Center